Advertisement

Acta Neuropathologica

, Volume 135, Issue 2, pp 299–301 | Cite as

Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas

  • Drew Pratt
  • Siva Kumar Natarajan
  • Adam Banda
  • Caterina Giannini
  • Pankaj Vats
  • Carl Koschmann
  • Rajen Mody
  • Arul Chinnaiyan
  • Sriram Venneti
Correspondence

Diffuse midline gliomas harboring a recurrent H3 lysine 27-to-methionine (p.Lys27Met, H3K27M) constitute a recently defined pathologic entity with a particularly poor prognosis. They mainly occur in midline structures, such as the pons and thalamus of children and young adults, and are highly infiltrative [2]. More recently, case reports have described the H3K27M mutation in circumscribed (non-diffuse) gliomas, many of which are low-grade (e.g., pilocytic astrocytoma, ganglioglioma) [1, 3, 4, 5] (additional references are provided in Online Resource 1). Because of the rarity of these tumors, it is unknown whether they carry the poor clinical outcome ascribed to H3K27M-mutant infiltrating gliomas of the midline. Here, we address this gap in our knowledge by performing an integrated meta-analysis on collated clinical and pathologic data from published studies, data repositories, and collaborative efforts.

A systematic search of the literature was performed from 2012 to November, 2017....

Notes

Acknowledgements

The Venneti lab is supported by Grants from NCI K08 CA181475, Sidney Kimmel, St Baldrick’s, Claire McKenna, Chad Tough, Doris Duke, and Sontag Foundations, and the University of Michigan Pediatric Brain Tumor Initiative. We thank Dr. Kathryn McFadden's for original artwork.

Compliance with ethical standards

Conflict of interest

The authors declare no competing interests.

Supplementary material

401_2018_1805_MOESM1_ESM.docx (44 kb)
Supplementary material 1 (DOCX 44 kb)
401_2018_1805_MOESM2_ESM.xlsx (21 kb)
Supplementary material 2 (XLSX 21 kb)
401_2018_1805_MOESM3_ESM.tif (277 kb)
Supplementary material 3 (TIFF 277 kb)

References

  1. 1.
    Kleinschmidt-DeMasters BK, Donson A, Foreman NK, Dorris K (2017) H3 K27M mutation in gangliogliomas can be associated with poor prognosis. Brain Pathol 27:846–850.  https://doi.org/10.1111/bpa.12455CrossRefPubMedGoogle Scholar
  2. 2.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820.  https://doi.org/10.1007/s00401-016-1545-1Google Scholar
  3. 3.
    Nguyen AT, Colin C, Nanni-Metellus I, Padovani L, Maurage CA, Varlet P, Miquel C, Uro-Coste E, Godfraind C, Lechapt-Zalcman E et al (2015) Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathol Appl Neurobiol 41:403–408.  https://doi.org/10.1111/nan.12196CrossRefPubMedGoogle Scholar
  4. 4.
    Orillac C, Thomas C, Dastagirzada Y, Hidalgo ET, Golfinos JG, Zagzag D, Wisoff JH, Karajannis MA, Snuderl M (2016) Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation. Acta Neuropathol Commun 4:84.  https://doi.org/10.1186/s40478-016-0361-0CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pages M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, Fina F, Barets D, Barret E, Lacroix L et al (2018) Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathol 28:103–111.  https://doi.org/10.1111/bpa.12473CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Drew Pratt
    • 1
  • Siva Kumar Natarajan
    • 1
  • Adam Banda
    • 1
  • Caterina Giannini
    • 2
  • Pankaj Vats
    • 3
  • Carl Koschmann
    • 4
  • Rajen Mody
    • 4
  • Arul Chinnaiyan
    • 3
  • Sriram Venneti
    • 1
  1. 1.Department of PathologyUniversity of MichiganAnn ArborUSA
  2. 2.Laboratory Medicine and PathologyMayo ClinicRochesterUSA
  3. 3.Michigan Center for Translational PathologyAnn ArborUSA
  4. 4.Department of PediatricsUniversity of Michigan School of MedicineAnn ArborUSA

Personalised recommendations